KOSDAQ - Delayed Quote KRW

LigaChem Biosciences Inc. (141080.KQ)

98,900.00
-1,600.00
(-1.59%)
At close: May 9 at 3:30:18 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
125,898,140.99
125,898,140.99
34,145,640.06
33,412,042.60
32,157,006.37
Cost of Revenue
15,949,876.43
15,949,876.43
16,348,326.30
15,563,353.04
14,459,449.16
Gross Profit
109,948,264.56
109,948,264.56
17,797,313.76
17,848,689.56
17,697,557.21
Operating Expense
130,861,753
130,861,753
98,619,657
68,223,789
45,404,218
Operating Income
-20,913,488.44
-20,913,488.44
-80,822,343.24
-50,375,099.44
-27,706,660.79
Net Non Operating Interest Income Expense
19,471,300.93
19,471,300.93
5,279,795.10
3,981,340.97
832,545.47
Pretax Income
9,125,066.39
9,125,066.39
-75,746,558.08
-47,722,617.78
-20,523,029.67
Tax Provision
1,324,966.81
1,324,966.81
-2,042,987.60
-2,630,824.20
2,868,197.92
Net Income Common Stockholders
7,800,099.57
7,800,099.57
-73,703,570.47
-45,091,793.57
-23,391,227.60
Basic EPS
227.00
--
-2.60k
-1.61k
-970.00
Diluted EPS
224.00
--
-2.60k
-1.61k
-970.00
Basic Average Shares
34,361.67
--
28,402.15
28,024.73
24,114.67
Diluted Average Shares
34,821.87
--
28,402.15
28,024.73
24,114.67
Total Operating Income as Reported
-20,913,487.72
-20,913,487.72
-80,822,342.64
-50,375,099.03
-27,706,660.41
Total Expenses
146,811,629.43
146,811,629.43
114,967,983.30
83,787,142.04
59,863,667.16
Net Income from Continuing & Discontinued Operation
7,800,099.57
7,800,099.57
-73,703,570.47
-45,091,793.57
-23,391,227.60
Normalized Income
3,526,247.96
3,526,247.96
-71,228,232.31
-40,911,567.62
-23,653,936.85
Interest Income
19,974,507
19,974,507
5,808,055
4,267,092
901,310
Interest Expense
503,207
503,207
528,260
285,751
68,765
Net Interest Income
19,471,300.93
19,471,300.93
5,279,795.10
3,981,340.97
832,545.47
EBIT
9,628,273.39
9,628,273.39
-75,218,298.08
-47,436,866.78
-20,454,264.67
EBITDA
14,637,182.39
14,637,182.39
-70,546,360.08
-43,318,853.78
-17,405,123.67
Reconciled Cost of Revenue
15,949,876.43
15,949,876.43
16,348,326.30
15,563,353.04
14,459,449.16
Reconciled Depreciation
5,008,909
5,008,909
4,671,938
4,118,013
3,049,141
Net Income from Continuing Operation Net Minority Interest
7,800,099.57
7,800,099.57
-73,703,570.47
-45,091,793.57
-23,391,227.60
Total Unusual Items Excluding Goodwill
4,999,831
4,999,831
-2,543,952
-4,424,116
350,279
Total Unusual Items
4,999,831
4,999,831
-2,543,952
-4,424,116
350,279
Normalized EBITDA
9,637,351.39
9,637,351.39
-68,002,408.08
-38,894,737.78
-17,755,402.67
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
725,979.39
725,979.39
-68,613.84
-243,890.05
87,569.75
12/31/2021 - 5/10/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

365270.KQ curacle co.,ltd.
6,590.00
-1.35%
 
378800.KQ Shaperon Inc.
2,880.00
-3.36%
 
397030.KQ AprilBio Co.,Ltd.
15,820.00
-2.29%
 
358570.KQ GI Innovation, Inc.
14,960.00
+4.47%
 
226950.KQ OliX Pharmaceuticals, Inc
43,500.00
-8.32%
 
196170.KQ ALTEOGEN Inc.
345,000.00
-2.13%
 
STTK Shattuck Labs, Inc.
0.9479
+0.88%
 
PMVP PMV Pharmaceuticals, Inc.
0.8827
-0.12%
 
TBPH Theravance Biopharma, Inc.
8.98
-9.29%
 
CNTA Centessa Pharmaceuticals plc
12.30
-0.73%